Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2010 - 2026)

Catalyst Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at $46.7 million for Q1 2026.

• Quarterly Net Cash Flow fell 26.01% year-over-year to $46.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $175.2 million (down 35.17% YoY) and the FY2025 annual result came in at $191.6 million, down 49.56% from the prior year.
• Net Cash Flow was $46.7 million for Q1 2026 at Catalyst Pharmaceuticals, up from $19.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $172.8 million in Q1 2024 and bottomed at -$150.1 million in Q1 2023.
• A 5-year average of $33.8 million and a median of $42.3 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 2267.58% — and 2024, when it surged 351.38%.
• Catalyst Pharmaceuticals' Net Cash Flow stood at $42.3 million in 2022, then tumbled by 60.63% to $16.7 million in 2023, then jumped by 351.38% to $75.2 million in 2024, then plunged by 74.37% to $19.3 million in 2025, then jumped by 142.17% to $46.7 million in 2026.
• Business Quant data shows CPRX's Net Cash Flow at $46.7 million in Q1 2026, $19.3 million in Q4 2025, and $37.1 million in Q3 2025.